Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Targeting developmental pathways in children with cancer: what price success?

Gore L, DeGregori J, Porter CC.

Lancet Oncol. 2013 Feb;14(2):e70-8. doi: 10.1016/S1470-2045(12)70530-2. Review.

2.

Targeted approaches to childhood cancer: progress in drug discovery and development.

Hirsch S, Marshall LV, Carceller Lechon F, Pearson AD, Moreno L.

Expert Opin Drug Discov. 2015 May;10(5):483-95. doi: 10.1517/17460441.2015.1025745. Epub 2015 Apr 3. Review.

PMID:
25840490
3.

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Pérez-Herrero E, Fernández-Medarde A.

Eur J Pharm Biopharm. 2015 Jun;93:52-79. doi: 10.1016/j.ejpb.2015.03.018. Epub 2015 Mar 23. Review.

PMID:
25813885
4.

Clinical trials in paediatric oncology. Recommendations for the development of new anticancer agents.

Vassal G, Méry-Mignard D, Caulin C.

Therapie. 2003 May-Jun;58(3):229-46. English, French.

PMID:
14655318
5.
6.

Oncology drug discovery: planning a turnaround.

Toniatti C, Jones P, Graham H, Pagliara B, Draetta G.

Cancer Discov. 2014 Apr;4(4):397-404. doi: 10.1158/2159-8290.CD-13-0452.

7.

Targeted cancer therapies.

Yan L, Rosen N, Arteaga C.

Chin J Cancer. 2011 Jan;30(1):1-4.

8.

Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.

Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S, Schrappe M, Skolnik J, Bergman L, Bradley-Garelik MB, Saha V, Pearson A, Zwierzina H.

Eur J Cancer. 2015 Jan;51(2):218-24. doi: 10.1016/j.ejca.2014.10.029. Epub 2014 Nov 27.

9.

Exploiting tumor metabolism: challenges for clinical translation.

Vander Heiden MG.

J Clin Invest. 2013 Sep;123(9):3648-51. doi: 10.1172/JCI72391. Epub 2013 Sep 3.

10.

New drug development in childhood cancer.

Kearns P, Morland B.

Curr Opin Pediatr. 2014 Feb;26(1):37-42. doi: 10.1097/MOP.0000000000000054. Review.

PMID:
24362409
11.

Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.

Le Tourneau C, Diéras V, Tresca P, Cacheux W, Paoletti X.

Target Oncol. 2010 Mar;5(1):65-72. doi: 10.1007/s11523-010-0137-6. Epub 2010 Apr 2. Review.

PMID:
20361265
12.

[Future directions of anticancer drug development in Japan].

Akaza H, Kawai K, Tsuruo T, Tsukagoshi S, Aiba K, Shimada Y, Kakeji Y, Ishikawa H, Ikeda T, Nakamura S, Tamura T, Yamamoto N, Isonishi S, Hinotsu S, Hirose M, Katsura J.

Gan To Kagaku Ryoho. 2008 Feb;35(2):351-60. Japanese.

PMID:
18281781
13.

Challenges in prescribing drugs for children with cancer.

Paolucci P, Jones KP, del Carmen Cano Garcinuno M, Catapano M, Iolascon A, Ceci A.

Lancet Oncol. 2008 Feb;9(2):176-83. doi: 10.1016/S1470-2045(08)70030-5.

PMID:
18237852
14.

[New systemic therapies in oncology].

Zaman K, Ketterer N, Vulliémoz D, Stupp R, Leyvraz S.

Rev Med Suisse. 2005 May 18;1(20):1361-2, 1364-5. Review. French.

PMID:
15991629
15.

Functional differentiation of cytotoxic cancer drugs and targeted cancer therapeutics.

Winkler GC, Barle EL, Galati G, Kluwe WM.

Regul Toxicol Pharmacol. 2014 Oct;70(1):46-53. doi: 10.1016/j.yrtph.2014.06.012. Epub 2014 Jun 20.

PMID:
24956585
16.

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

Engel J, Emons G, Pinski J, Schally AV.

Expert Opin Investig Drugs. 2012 Jun;21(6):891-9. doi: 10.1517/13543784.2012.685128. Review.

PMID:
22577891
17.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd..

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
18.

Improving the outcome for children with cancer: Development of targeted new agents.

Adamson PC.

CA Cancer J Clin. 2015 May-Jun;65(3):212-20. doi: 10.3322/caac.21273. Epub 2015 Mar 9. Review.

19.

Targeted therapy: for kids, too.

Corey SJ.

Pediatr Blood Cancer. 2005 Oct 15;45(5):623-34. Review.

PMID:
15704219
20.

Current and future roles of targeted therapy and immunotherapy in advanced melanoma.

Olszanski AJ.

J Manag Care Spec Pharm. 2014 Apr;20(4):346-56. Review.

Supplemental Content

Support Center